Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab in Previously Treated Hepatocellular Carcinoma
CTR20222959Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab in hepatocellular carcinoma (HCC), sponsored by Janssen Pharmaceutical. Started Dec 2022; status: terminated.
02
Drugs
amivantamab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20222959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222959.